Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danazol plus cyclosporine versus cyclosporine in transfusion‑independent aplastic anemia after inadequate response
ChiCTR2000041485Phase 4Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of danazol in aplastic anemia (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Superior remission rate. Started Jan 2021; status: recruiting.
02
Drugs
danazol
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2000041485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041485.